In August 2015, the IMWG published the Revised International Staging System (R-ISS) for multiple myeloma to incorporate two further prognostic factors: genetic risk as assessed by …

The Multiple Myeloma International Staging System (ISS) prognosticates the severity of multiple myeloma based on routinely obtained lab values.

The Revised multiple Myeloma International Staging System (ISS) stages multiple myeloma patients based on genetics and routine lab values in conjunction with the original ISS.

Multiple myeloma is staged using the Revised International Staging System (R-ISS), which is based on 4 factors: *Samples from a bone marrow biopsy are typically tested to look at the …

2022年5月23日 · Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …

2005年5月20日 · CONCLUSION) The new ISS is simple, based on easy to use variables (Sbeta2M and serum albumin), and recommended for early adoption and widespread use. …

2015年8月3日 · We combined the International Staging System (ISS) with chromosomal abnormalities (CA) detected by interphase fluorescent in situ hybridization after CD138 plasma …

2005年5月20日 · There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification. Clinical and laboratory …

Calculate Multiple Myeloma prognosis using the International Staging System (ISS). Free online tool for medical professionals.

R-ISS能更好地区分初诊MM患者的OS时间，尤其对于接受硼替佐米治疗为主、年轻、未行移植患者的预后评估价值较为突出，对中国MM患者具有重要的预后价值。 To assess the prognostic …